SCHEMBL2525892

SCHEMBL2525892

CN1C(=O)NC(=O)C12CCN(C(=O)OCc1ccccc1)CC2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 5/20 0.53
CCR5 P51681 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
HTR1A P08908 2/20 0.52
HTR2C P28335 2/20 0.52
ADORA3 P0DMS8 1/20 0.52
SLC6A3 Q01959 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
CYP2C19 P33261 1/20 0.49
OPRM1 P35372 1/20 0.48
AVPR1A P37288 1/20 0.48
ENPP2 Q13822 1/20 0.47
ATXN2 Q99700 1/20 0.47
OPRD1 P41143 1/20 0.46
KDM1A O60341 1/20 0.46
TMEM97 Q5BJF2 4/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12340733 0.84 OPRK1 (0.58) OPRK1CCR5MEN1KMT2ANPSR1
SCHEMBL6622580 0.84 OPRK1 (0.53) OPRK1CCR5MEN1KMT2ANPSR1
SCHEMBL3508359 0.84 CCR5 (0.66) OPRK1CCR5MEN1KMT2ANPSR1
SCHEMBL10500680 0.81 MEN1 (0.56) OPRK1CCR5MEN1KMT2ANPSR1
SCHEMBL30413961 0.78 OPRK1 (0.54) OPRK1CCR5MEN1KMT2ANPSR1
SCHEMBL25709613 0.78 MEN1 (0.58) OPRK1MEN1KMT2ANPSR1HTR1A
SCHEMBL17140589 0.78 MEN1 (0.52) OPRK1CCR5MEN1KMT2ANPSR1
SCHEMBL318741 0.78 OPRK1 (0.83) OPRK1CCR5HTR1AHTR2CADORA3
SCHEMBL566838 0.78 MEN1 (0.61) OPRK1MEN1KMT2ANPSR1HTR1A
SCHEMBL23055440 0.78 MEN1 (0.54) OPRK1MEN1KMT2ANPSR1HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8039460-B2 CGRP (Calcitonin Gene-Related Peptide); migraine and cluster headache; compounds based on 6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine or 6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepine MERCK SHARP & DOHME CORP. (US) 2011-10-18 US disclosed
EP-1802637-B1 CGRP RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2008-10-15 EP disclosed
US-20080113966-A1 Cgrp Receptor Antagonists MERCK SHARP & DOHME LLC 2008-05-15 US disclosed
EP-1802637-A1 CGRP RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2007-07-04 EP disclosed
WO-2006044504-A1 CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113966-A1 Cgrp Receptor Antagonists BDKRB1, BDKRB2, CCKBR OPRK1 73/4885CCR5 395/4885MEN1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.